(News Bulletin 247) – Pfizer today announced the publication in The Lancet Neurology of results from the pivotal Phase 3 clinical trial of Zavegepant, an investigational calcitonin gene-related peptide (CGRP) receptor antagonist spray nasal for the acute treatment of migraine.
The study met its endpoints showing that a single 10 mg dose of Zavegepant was more effective than placebo for resolution of pain and most bothersome symptom (MBS) two hours post-dose.
Additionally, Zavegepant provided migraine pain relief within 15 minutes, with relief lasting up to 48 hours in many patients. Zavegepant was well tolerated and no serious adverse events were reported in treated participants.
“With this evidence of sustained treatment benefits, good tolerability and an alternative method of administration, I believe Zavegepant has the potential to fill a gap in the options available for the acute treatment of migraine,” said Richard B Lipton, MD, senior author, Department of Neurology, Albert Einstein College of Medicine.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
